Will NVIDIA Be Knocked Off Its Perch By Quantum?
Earlier this month, NVIDIA CEO Jensen Huang seemingly dashed the hopes of speculative tech investors banking on quantum computing to become the next big thing in the ever-advancing race for faster and faster computer processing. Huang, speaking at the Consumer Electronics Show, stated his view that practical quantum computers were still about two decades away, causing a selloff among the stocks of quantum startups. » Read more about: Will NVIDIA Be Knocked Off Its Perch By Quantum? »
Read More
1 Organ Transplant Disruptor to Buy on the Dip
TransMedics (NASDAQ:TMDX) is an innovative biotechnology company that may well have the potential to disrupt the $11 billion organ transplant industry.
The company’s unique organ care system technology protects and monitors donor organs before they are transplanted into patients, resulting in improved organ health and outcomes. TransMedics also provides logistical services,
» Read more about: 1 Organ Transplant Disruptor to Buy on the Dip »
Read More
Brilliant Billionaire Buys Under-the-Radar Wide Moat Stock
In B2B sales and marketing, few companies have built as powerful a toolset as the one that caught Stan Druckenmiller’s eye.
With a unique moat in its vast proprietary database, accelerating AI-driven insights, and a growing foothold in emerging markets, this SaaS firm has become a must-have resource for enterprise sales teams.
Yet while bulls can point to a host of positive attributes,
» Read more about: Brilliant Billionaire Buys Under-the-Radar Wide Moat Stock »
Read More
Is Bitcoin $100,000 Next?
Bitcoin has been on a tear lately, bringing its YTD returns to over 112%. Much of this gain can be attributed to Donald Trump’s support of bitcoin and his electoral victory, which added to an already bullish period for Bitcoin.
Now, the big question is whether the benchmark cryptocurrency could cross the $100,000 mark for the first time in the near future.
» Read more about: Is Bitcoin $100,000 Next? »
Read More
Billionaire Buys Stake In Gene Therapy Stock
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment,
» Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Read MoreThe Ivy
1 Cash Cow with Massive Upside
CVS Health (NYSE:CVS) share price declined by over 23% over the past twelve months. Hurting shareholders was the recent leadership transition from CEO Karen Lynch to David Joyner, a shift that brought uncertainty to the company’s direction as investors questioned the company’s stability while facing ongoing challenges.
» Read more about: 1 Cash Cow with Massive Upside »
Read MoreThe Spotlight
You Can’t Pick Tesla, So Which EV Wins?
Few realize that Lucid Group (NASDAQ: LCID) traces part of its engineering DNA back to Atieva, a company that initially specialized in developing advanced battery systems for Formula E racing teams. Before the high-profile splash of the Lucid Air sedan, Lucid’s engineers were quietly perfecting electric drivetrains in the crucible of motorsports.
This racing pedigree helped the company engineer a powertrain that offers truly impressive range—up to 516 miles on a single charge for the Lucid Air Grand Touring edition,
» Read more about: You Can’t Pick Tesla, So Which EV Wins? »
Read MoreThe Daily
1 Magnificent S&P 500 Dividend Stock Down 31% to Buy and Hold Forever
The underpinnings of its multi-year weakness are finally abating, and this dividend payer is emerging stronger than ever.
Like bargains? You should. Although you’re often required to pay a premium for quality, if you can get the quality you want at a lower price, so much the better!
Income-seeking investors may want to consider taking on a new position in Realty Income Corporation (O 1.01%) while this dividend stock is down 31% from its highest-ever high.
» Read more about: 1 Magnificent S&P 500 Dividend Stock Down 31% to Buy and Hold Forever »